Pharmaceuticals
B dot Medical Successfully Develops Compact Scanning Magnet for Proton Cancer Therapy System
TOKYO, Sept. 9, 2021 /PRNewswire/ -- B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at its factory, for a compact proton cancer therapy system under development, and confirmed the generation of a magnetic field. That means a major ...
2021-09-09 15:00
1667
Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) licensed for manufacturing, which actively promotes vaccine export and improves vaccine accessibility
SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its Recombinant COVID-19 Vaccine(Adenovirus ...
2021-09-09 11:40
4159
Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met
SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of pyrilutamide ("KX-8...
2021-09-08 22:13
4628
The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare
Partnership will bring first GMP manufactured products to be sold through Valens in bothAustralia and New Zealand Access to Epsilon's GMP facility in Australia to provide Valens with future access to global markets includingLatin America, Europe, UK and Asia-Pacific KELOWNA, BC, Sept. 8, 2021 ...
2021-09-08 19:00
4086
Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant
SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announceSaibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter E...
2021-09-06 13:44
4260
GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates
SUZHOU, China, Sept. 5, 2021 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co.,Ltd. (hereinafter referred to as "GeneQuantum") and BrighGene Biomedical (Suzhou) Co.,Ltd. (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1...
2021-09-06 09:00
1752
AffaMed Therapeutics Enters into Strategic Partnership Agreement with Beijing Tiantan Hospital and Infinite Brain Technologies to Promote Digital Therapy in Neurological Diseases
BEIJING, Sept. 5, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, announced during the recent "China International Trade in Servi...
2021-09-06 08:00
1535
WuXi AppTec Receives AA ESG Rating from MSCI
SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of "corporate governance" and "product safety and quality...
2021-09-06 08:00
3202
PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC
DAEJEON, South Korea, Sept. 3, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company has received Human Research Ethics Committee (HREC) clearance to commence the Phase II c...
2021-09-03 20:00
2298
I-Mab Added to FTSE Russell Global Equity Index Series
SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Eq...
2021-09-02 20:00
6457
Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed
TAIPEI and SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its oral new drug, Silmitasertib, had received a positive feedbac...
2021-08-31 19:00
1940
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial
* Topical treatment safe and well tolerated in study of healthy volunteers * Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure * Collaboration with research team led by Professor Fiona Wood AM planning for trial in patients with established scars to com...
2021-08-31 18:00
1798
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021
* 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 * Felzartamab (TJ...
2021-08-31 18:00
3762
Harbour BioMed Reports 2021 Interim Results
CAMBRIDGE, Mass.and SUZHOU, China and ROTTERDAM, Netherlands, Aug. 31, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, reported its interim...
2021-08-31 13:47
4048
InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723
BEIJING, Aug. 30, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biopharmaceutical company, announced today the Investigational New Drug (IND) clearance of its second-generation pan-TRK inhibitor ICP-723 by the US Food and Drug Administration (FDA) for starting phase I cli...
2021-08-31 08:30
2811
Through CEO of Hanmi Science, CancerRop Issues KRW 20 Billion New Shares for Cooperation with Oxford Vacmedix
SEOUL, South Korea, Aug. 30, 2021 /PRNewswire/ -- CancerRop (180400), a company specializing in precision medicine and molecular diagnostics, announced a jump start in the global vaccine hub for COVID-19 mRNA (messenger ribonucleic acid) with Hanmi Science through20 billion won worth of investmen...
2021-08-30 23:00
3563
I-Mab Announces Upcoming Participation at September Conferences
SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Septem...
2021-08-30 20:00
2035
GeneQuantum announces Dr. Yi Xia as Senior Vice President of Statistics and Data Science
SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr.Yi Xia as Seni...
2021-08-30 10:00
2279
InnoCare Releases 2021 Half Year Results and Business Highlights
BEIJING, Aug. 29, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 half year results which ended onJune 30, 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "On the fo...
2021-08-29 19:49
5014
IONOVA Life Science Announces New Financing Round of USD $100 Million
SHENZHEN, China, Aug. 27, 2021 /PRNewswire/ -- On August 27, 2021, Shenzhen IONOVA Life Science Co., Ltd. ("IONOVA" or "the company"), a clinical-stage biotechnology company located in theGuangdong-Hong Kong-Macao Greater Bay Area ofChina, announced completion of a new financing round of USD $100...
2021-08-27 22:00
3227
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
6137
